Medical Simulation Medical Graphic
Medical Animation | Mechanism of Action | Medical Print Illustration | Holo 3D | General 3D | Contact

Liver Animation – Hepatitis Animation


Medical animations used for medical education and method of action videos. Hepatitis animation also 3d liver illustrations and cirrhosis illustrations method of action video. Liver disease 3d medical illustrations. Custom 3d Hepatitis illustrations and 3d liver illustrations MOA for print campaigns.

Transplant Program At UT Southwestern University Hospital Recognized For Increasing Organ Donor Rates
The surgical transplant team at UT Southwestern University Hospital has garnered twin awards for its successful efforts to increase organ donation rates. "Each organ donation is an opportunity for new life, so we are gratified with these recognitions," said Dr. Juan Arenas, chief of surgical transplantation and surgical director for the liver transplant program.
Debunking The Detox Myth
A group of over 300 young UK scientists and engineers who investigated the evidence behind claims made for products and diets, have started a public awareness campaign by publishing a dossier that shows the word "detox" has no meaning outside of the clinical treatment of drug addiction and poisoning. Called the "Detox Dossier", the report describes the findings of the investigation by the Voice of Young Science (VoYS) network of over 300 early career researchers.
A Rigorous Method For Liver Biopsy
Liver biopsy is still considered the gold standard for grading, staging and "stad-ging" the chronic liver disease. In addition, it remains a primary source for acquiring new knowledge on the liver pathology.
Dynavax Announces Termination Of Partnership With Merck For HEPLISAV™ Hepatitis B Vaccine - All Rights Revert To Dynavax
Dynavax Technologies Corporation (Nasdaq:DVAX) today announced the termination of a global license and development collaboration agreement with Merck & Co., Inc. for HEPLISAVTM, a Phase 3 hepatitis B virus (HBV) vaccine. All rights to develop and commercialize HEPLISAV revert to Dynavax.
Molecular Events Involved In Liver Regeneration
The ability to regenerate after major tissue damage or surgical intervention is an important property of the liver. Since liver resection is an established therapeutic measure for severe liver diseases, it would be of importance to know which molecular events underly the regenerative process and if they depend on the extent of resection, as indicated in previous studies. The group led by Prof.
Molecular Events Involved In Liver Regeneration
The ability to regenerate after major tissue damage or surgical intervention is an important property of the liver. Since liver resection is an established therapeutic measure for severe liver diseases, it would be of importance to know which molecular events underly the regenerative process and if they depend on the extent of resection, as indicated in previous studies. The group led by Prof.
Liver Cancer Hope - Acculis Microwave Tissue Ablation System Worldwide Launch Extended In Europe, The Americas And Asia
Acculis Limited, the leading UK microwave ablation system company, today announced the extension of the worldwide launch of their pioneering Microwave Tissue Ablation (MTA) system for the coagulation of soft tissue in open surgery. The system is being used by the world's best liver surgeons to treat liver cancers. MTA is the only FDA 510(k) cleared single needle high power 2.45GHz microwave system. It achieves 5cm x 6.5cm coagulations with single 8 minute applications and 4.
Using Math To Understand Hep. C: Patterns Paint Picture Of Who Will Respond To Treatment
Genetic patterns are like the tea leaves in the bottom of a cup for predicting which patients are likely to respond to medical therapy for life-threatening viruses such as hepatitis C, Saint Louis University researchers have discovered. Their findings are published in the Dec. 22 early online issue of the Journal of Clinical Investigation.
Math Patterns Show Who Will Respond To Hep C Treatment
Genetic patterns are like the tea leaves in the bottom of a cup for predicting which patients are likely to respond to medical therapy for life-threatening viruses such as hepatitis C, Saint Louis University researchers have discovered. Their findings are published in the Dec. 22 early online issue of the Journal of Clinical Investigation.
FDA Clears Covidien's Evident™ Microwave Ablation System For Use In Nonresectable Liver Tumor Ablation
Covidien (NYSE: COV, BSX: COV), a leading global provider of healthcare products , today announced that the United States Food and Drug Administration (FDA) has issued a 510(k) marketing clearance for the Evident™ Microwave (MW) Ablation System, intended for use in the ablation of nonresectable liver tumors. This new system offers a procedural option for patients who are not candidates for surgical resection and have few remaining treatment options.
The Office Of Minority Health Releases Strategies To Address Chronic Hepatitis B In Asian American, Native Hawaiian And Other Pacific Islander
More health education, awareness and screenings, improved access to care and treatment, and increased research are needed to reduce and eventually eliminate chronic hepatitis B among Asian-Americans, Native Hawaiians and Other Pacific Islander communities (AAs/NHOPIs), a federal report recommends.
Sorafenib Is Effective In Asian-Pacific Patients With Advanced Liver Cancer
Sorafenib significantly increases overall survival in Asian-Pacific patients with advanced hepatocellular carcinoma - a group where surgical treatments can be limited - according to findings of a phase III trial reported in an Article published early Online and in the January edition of The Lancet Oncology. Hepatocellular carcinoma is the third most common cause of cancer-related death and is a particular challenge in the Asia-Pacific region, where 75% of cases occur.
Efforts Seek To Reduce Racial Health Disparities, Raise Hepatitis B Awareness Among Asian Communities
The following highlights efforts that seek to reduce racial and ethnic health disparities.
Schering Plough Announces FDA Approval Of PEGINTRON(TM) And REBETOL(R) Combination Therapy For Treating Pediatric Hepatitis C
Schering-Plough Corporation (NYSE: SGP) announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval to PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy for use in previously untreated patients 3 years of age and older with chronic hepatitis C. This represents the first and only approved peginterferon in combination with ribavirin for treating pediatric hepatitis C.
Schering-Plough Announces FDA Approval Of PEGINTRON(TM) And REBETOL(R) Combination Therapy For Treating Pediatric Hepatitis C
First and only approved peginterferon in combination with ribavirin for previously untreated children with chronic hepatitis C addresses unmet medical need Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval to PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy for use in previously untreated patients 3 years of age and older with chronic hepatitis C.
WindowsFlashQuicktime
Request Demo Reel DVD
Related Medical Animation Links

Copyright © 2007
Content Management / Website Design by Tresware